LIXTE Biotechnology Appoints Sidney Braun to Lead European Proton Therapy Subsidiary

LIXTE Biotechnology Holdings announced the appointment of Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary. Braun, who previously facilitated LIXTE's November 2025 acquisition of Liora's assets, brings more than 20 years of healthcare operational and strategic advisory experience to the role. This appointment represents a strategic move to accelerate development of Liora's LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment precision and effectiveness.

The LiGHT System represents a significant advancement in proton therapy technology, which uses precisely targeted proton beams to destroy cancer cells while minimizing damage to surrounding healthy tissue. Proton therapy has emerged as a critical treatment modality for various cancers, particularly those located near vital organs or in pediatric patients where radiation exposure must be carefully controlled. The technology's potential to improve treatment outcomes while reducing side effects makes it a valuable addition to the oncology treatment arsenal.

Management indicated that Braun's appointment supports LIXTE's broader strategy to scale the LiGHT technology and pursue a recurring revenue model within the radiotherapy segment of cancer care. This approach aligns with growing market demand for advanced cancer treatment technologies and the increasing adoption of proton therapy in clinical settings worldwide. The European subsidiary structure allows LIXTE to better serve the European market while maintaining focus on its core pharmaceutical development programs.

LIXTE Biotechnology Holdings is primarily known for its clinical-stage pharmaceutical development, particularly its first-in-class lead clinical PP2A inhibitor, LB-100. The company has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has shown potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. The company's lead compound represents a pioneering effort in activation lethality, an entirely new field of cancer biology that is advancing a new treatment paradigm.

The expansion into proton therapy through the Liora Technologies Europe subsidiary represents a diversification of LIXTE's cancer treatment portfolio. While the company continues to advance its pharmaceutical programs, including proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer, the proton therapy platform offers complementary therapeutic capabilities. This dual approach positions LIXTE to address cancer treatment through both pharmaceutical and technological interventions, potentially creating synergies between different treatment modalities.

The appointment of Braun, with his extensive experience in healthcare operations and strategic advisory roles, suggests LIXTE is serious about establishing a significant presence in the proton therapy market. His previous involvement in facilitating the acquisition of Liora's assets provides continuity and deep understanding of the technology's potential and challenges. As proton therapy continues to gain acceptance and reimbursement support in healthcare systems globally, LIXTE's strategic positioning through its European subsidiary could provide competitive advantages in technology adoption and market penetration.